Recently-floated PLx Pharma (Nasdaq: PLXP) has made two new executive appointments, hiring Rita O’Connor as chief financial officer and Michael Dillon as vice president of sales and marketing.
PLx Pharma is a late-stage specialty pharmaceutical company focused on developing improved delivery systems for aspirin products.
Ms O’Connor, former CFO of Mucinex Innovator and Adams Respiratory Therapeutics, is said by the company to bring “an extensive background in finance, strategic partnering, merger and acquisitions and equity fundraising.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze